Detalhe da pesquisa
1.
Interim safety and immunogenicity results from an NDV-based COVID-19 vaccine phase I trial in Mexico.
NPJ Vaccines
; 8(1): 67, 2023 May 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37164959
2.
Safety and immunogenicity of a live recombinant Newcastle disease virus-based COVID-19 vaccine (Patria) administered via the intramuscular or intranasal route: Interim results of a non-randomized open label phase I trial in Mexico.
medRxiv
; 2022 Feb 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-35169806
3.
Safety and Immunogenicity of a Newcastle Disease Virus Vector-Based SARS-CoV-2 Vaccine Candidate, AVX/COVID-12-HEXAPRO (Patria), in Pigs.
mBio
; 12(5): e0190821, 2021 10 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-34544278